Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00632359 |
The goal of this clinical research study is to learn if Revlimid™ (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.
Condition | Intervention | Phase |
---|---|---|
Chronic Lymphocytic Leukemia |
Drug: Lenalidomide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270 |
Estimated Enrollment: | 52 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | August 2010 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Lenalidomide
|
Drug: Lenalidomide
Lenalidomide 10mg daily
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Alessandra Ferrajoli, M.D. | 713-792-2063 | aferrajo@mdanderson.org |
United States, Texas | |
The University of Texas M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Alessandra Ferrajoli, M.D. 713-792-2063 aferrajo@mdanderson.org |
Principal Investigator: | Alessandra Ferrajoli, M.D, | M.D. Anderson Cancer Center |
Responsible Party: | The University of Texas M. D. Anderson Cancer Center ( Alessandra Ferrajoli, M.D./Associate Professor ) |
Study ID Numbers: | 2007-0213 |
Study First Received: | March 3, 2008 |
Last Updated: | February 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00632359 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Chronic Lymphocytic Leukemia CLL Lenalidomide Revlimid |
Lymphatic Diseases Leukemia Chronic Lymphocytic Leukemia Leukemia, Lymphoid Immunoproliferative Disorders |
Leukemia, Lymphocytic, Chronic, B-Cell Lenalidomide Leukemia, B-cell, Chronic Lymphoproliferative Disorders Leukemia, B-Cell |
Leukemia, Lymphoid Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents Lenalidomide Pharmacologic Actions |
Leukemia Lymphatic Diseases Neoplasms Leukemia, Lymphocytic, Chronic, B-Cell Therapeutic Uses Leukemia, B-Cell Lymphoproliferative Disorders |